The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
Abstract
Selective inhibition of BCL-X L synergizes with docetaxel to inhibit the growth of solid tumors but does not inhibit granulopoiesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The use of Bcl-xl inhibitors as senolytics is largely limited by their on-target and dose-limiting platelet toxicity.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
In the citing paper
“Bcl-xl inhibition with ABT263 and other small molecular inhibitors induces platelet apoptosis and results in severe thrombocytopenia, which prevents the use of ABT263 and other Bcl-xl specific inhibitors in the clinic—even for cancer patients—because platelets solely depend on Bcl-xl for survival24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
In the citing paper
“As reported, ABT263 was highly toxic to both WI38 IR-SCs (Fig. 1g, middle panel) and platelets16–18,24–27 (Fig. 1g, right panel; Supplementary Fig. 2).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
In the citing paper
“Because both SCs and platelets, but not NCs, are primarily dependent on Bcl-xl for survival16–18,24–27 (Supplementary Fig. 1h), we evaluated the effects of PZ compared with ABT263 on the viability of WI38 NCs (Fig. 1g, left panel), IR-SCs (Fig. 1g, middle panel), and platelets (Fig. 1g, right panel).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
In the citing paper
“Therefore, PZ can selectively induce apoptosis in SCs, but not platelets, which are dependent on Bcl-xl for survival while having minimal toxicity to NCs that are less sensitive to Bcl-xl inhibition than SCs16–18,24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
In the citing paper
“The inability of PZ to efficiently induce Bcl-2 degradation may provide additional advantages for using PROTAC technology to reduce ABT263 on-target toxicity because Bcl-2 inhibition with a high dose or an intensive treatment regimen of ABT263 can lead to neutropenia and lymphocytopenia25.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
Self-citationControl of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Self-citationClinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Self-citationNovack, D. V., Sorenson, C. M., Shutter, J. R., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80065-m · Cited by 1,637
Chipuk, J. E., Moldoveanu, T., Llambi, F., Parsons, M. J., & Green, D. R. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.025 · Cited by 1,476
Certo, M. V., Moore, V. D. G., Nishino, M., Wei, G., Korsmeyer, S. J., Armstrong, S. A., & Letai, A. G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.027 · Cited by 1,278
van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,271
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 548
Abo-Elfadl, M. T., Gamal‐Eldeen, A. M., Ismail, M. F., & Shahin, N. N. (2019) · Cytokine · doi:10.1016/j.cyto.2019.154790 · Cited by 23
BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the Clinic
Lin, V. S., Xu, Z., Huang, D. C. S., & Thijssen, R. (2020) · Cancers · doi:10.3390/cancers12113353 · Cited by 24
Müller, D., Mazzeo, P., Koch, R., Bösherz, M.-S., Welter, S., von Hammerstein-Equord, A. F., Hinterthaner, M., Cordes, L., Belharazem, D., Marx, A., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02158-3 · Cited by 20
BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer
Ramesh, P., Franco, S. D., Taboada, L. A., Zhang, L., Nicotra, A., Stassi, G., & Medema, J. P. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110374 · Cited by 23
Karbon, G., Haschka, M. D., Hackl, H., Soratroi, C., Rocamora‐Reverte, L., Parson, W., Fiegl, H., & Villunger, A. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04415-y · Cited by 21
Tumor-targeted liposomes with platycodin D2 promote apoptosis in colorectal cancer
Cho, E., Mun, S., Jeon, M., Kim, H. K., Baek, H., Ham, Y. S., Gil, W. J., Kim, J. W., & Yang, C. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100745 · Cited by 23
Ren, W., Joshi, R., & Mathew, P. F. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0202 · Cited by 22
IL-13 in LPS-Induced Inflammation Causes Bcl-2 Expression to Sustain Hyperplastic Mucous cells
Chand, H. S., Harris, J. F., & Tesfaigzi, Y. (2018) · Scientific Reports · doi:10.1038/s41598-017-18884-9 · Cited by 22
BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer
Lochmann, T. L., Bouck, Y. M., & Faber, A. C. (2018) · Oncoscience · doi:10.18632/oncoscience.455 · Cited by 22
Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis
Xu, D., Liang, S., Zhang, Y., Yang, H., Bruggmann, R., Oberhaensli, S., Berezowska, S., Marti, T. M., Hall, S. R. R., Dorn, P., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03668-x · Cited by 25
Yang, X., Li, Y., Chen, L., Xu, M., Wu, J., Zhang, P., Nel, D., & Sun, B. (2020) · Pharmaceutical Biology · doi:10.1080/13880209.2020.1784237 · Cited by 21
Delbridge, A. R. D., Aubrey, B. J., Hyland, C. D., Bernardini, J. P., Rago, L. D., Garnier, J., Lessène, G., Strasser, A., Alexander, W. S., & Grabow, S. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.304 · Cited by 21
Soond, S. M., Kozhevnikova, M. V., Savvateeva, L. V., Townsend, P. A., & Zamyatnin, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094669 · Cited by 21
Sejic, N., George, L. C., Tierney, R. J., Chang, C. W. T., Kondrashova, O., MacKinnon, R. N., Lan, P., Bell, A. I., Lessène, G., Long, H. M., et al. (2020) · PubMed Central · doi:10.1182/bloodadvances.2020002446 · Cited by 20
BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
Arulananda, S., O’Brien, M., Evangelista, M., Harris, T. J., Steinohrt, N. S., Jenkins, L. J., Walkiewicz, M., O’Donoghue, R. J. J., Poh, A. R., Thapa, B., et al. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00348-1 · Cited by 22
Chiou, J., Wu, Y., Lee, Y., & Chang, L. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115738 · Cited by 20
Palominos, C., Fuentes-Retamal, S., Salazar, J. P., Guzmán‐Rivera, D., Correa, P., Mellado, M., Araya‐Maturana, R., & Urra, F. A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216965 · Cited by 21
Izutsu, K., Yamamoto, K., Kato, K., Ishikawa, T., Fukuhara, N., Terui, Y., Choi, I., Humphrey, K., Kim, S. Y., Okubo, S., et al. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-03024-3 · Cited by 21
Arulananda, S., Lee, E. F., Fairlie, W. D., & John, T. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1856660 · Cited by 19
Lv, M., Hu, W., Zhang, S., He, L., Hu, C., & Yang, S. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215716 · Cited by 19
Nocquet, L., Roul, J., Lefebvre, C. C., Duarte, L., Campone, M., Juin, P. P., & Souazé, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-64696-z · Cited by 22
BAK/BAX-Mediated Apoptosis Is a Myc-Induced Roadblock to Reprogramming
Kim, E. J. Y., Änkö, M., Flensberg, C., Majewski, I. J., Geng, F., Firas, J., Huang, D. C. S., van Delft, M. F., & Heath, J. K. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.12.019 · Cited by 19
Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer
Vallet, S., Fan, F., Malvestiti, S., Pecherstorfer, M., Sattler, M., Schneeweiß, A., Schulze‐Bergkamen, H., Opferman, J. T., Cardone, M. H., Jäger, D., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-5022-5 · Cited by 19
Cell Death Pathways in Lymphoid Malignancies
Fletcher, L. B., Nabrinsky, E., Liu, T., & Danilov, A. V. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0874-3 · Cited by 20
Structure-Based Design of A-1293102, a Potent and Selective BCL-XL Inhibitor
Tao, Z., Wang, X., Chen, J., Ingram, J. P., Jin, S. S., Judge, R. A., Kovar, P. J., Park, C., Sun, C. C., Wakefield, B. D., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00162 · Cited by 21
Self-citationCarrington, E. M., Louis, C., Kratina, T., HANCOCK, M. S., Keenan, C. R., Iannarella, N., Allan, R. S., Wardak, A. Z., Czabotar, P. E., Herold, M. J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004139 · Cited by 19
Reljić, B., Conos, S. A., Lee, E. F., Garnier, J., Li, D., Lessène, G., Fairlie, W. D., Vaux, D. L., & Lindqvist, L. (2016) · Autophagy · doi:10.1080/15548627.2016.1179406 · Cited by 19
Boghaert, E. R., Cox, M. C., & Vaidya, K. S. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3236 · Cited by 17
Self-citationRole of cellular senescence in hepatic diseases (Review)
Xing, Y., & Zhu, J. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5623 · Cited by 19
Yang, X., Chen, L., Li, Y., Gao, F., Yan, Z., Zhang, P., Wu, J., Wang, H., & Sun, B. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135258 · Cited by 18
Xu, W., Zhao, T., Chen, H., Huang, N., Gong, H., Zhang, J., Yu, Y., Li, T., Zhang, G., Gong, C., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115045 · Cited by 20
Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins
Pal, P., Zhang, P., Poddar, S. K., & Zheng, G. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2116311 · Cited by 18
Targeting Cancer's Achilles’ Heel: Role of BCL-2 Inhibitors in Cellular Senescence and Apoptosis
Anantram, A., & Degani, M. S. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0366 · Cited by 18
Wu, G., Yuan, Z., Chen, M., Tang, X., Wang, F., & Zhang, D. (2026) · Molecules · doi:10.3390/molecules31071180 · Cited by 17
Wu, Q., Li, R., Wang, Q., Zhang, M., Liu, T., & Qu, Y.-Q. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03457-w · Cited by 18
A photothermal driven chemotherapy for the treatment of metastatic melanoma
Bhatt, H., Diwan, R., Borrego, E. A., Perez, C. A., Varela-Ramírez, A., Kumar, R., Aguilera, R. J., & Nurunnabi, M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.005 · Cited by 17
Hardouin, C., Baillard, S., Barière, F., Copin, C., Craquelin, A., Janvier, S., Lemaitre, S., Roux, S. L., Russo, O., & Samson, S. (2019) · Organic Process Research & Development · doi:10.1021/acs.oprd.9b00364 · Cited by 17
Small molecules targeting Mcl-1: the search for a silver bullet in cancer therapy
Nhu, D., Lessène, G., Huang, D. C. S., & Burns, C. J. (2016) · MedChemComm · doi:10.1039/c5md00582e · Cited by 16
Small molecule SJ572946 activates BAK to initiate apoptosis
Sekar, G., Singh, G., Qin, X., Guibao, C. D., Schwam, B., Inde, Z., Grace, C. R., Zhang, W., Slavish, P. J., Lin, W., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105064 · Cited by 15
The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia
Besbes, S., Pocard, M. D., Mirshahi, M., & Billard, C. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.02.003 · Cited by 18
Szymański, P., Olszewska, P., Mikiciuk‐Olasik, E., Różalski, A., Maszewska, A., Markiewicz, Ł., Cuchra, M., & Majsterek, I. (2017) · Tumor Biology · doi:10.1177/1010428317695011 · Cited by 16
Pharmacologic Control of CAR T Cells
Caulier, B., Enserink, J. M., & Wälchli, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094320 · Cited by 17
Specific Targeting of Antiapoptotic Bcl-2 Proteins as a Radiosensitizing Approach in Solid Tumors
Sobol, B., Nieto, O. A., Eberlein, E. L., Scherr, A., Ismail, L., Kessler, A., Nader, L., Schwab, M., Hoffmeister‐Wittmann, P., Schmitt, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147850 · Cited by 17
Ivanov, V., Yeh, S., Mayer, J., Saini, L., Ünal, A., Boyiadzis, M. M., Hoffman, D., Kang, K., Addo, S. N., Mendes, W., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0450 · Cited by 16
Stutz, M. D., Ojaimi, S., Ebert, G., & Pellegrini, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01178 · Cited by 16
Preferential targeting of MCL-1 by a hydrocarbon-stapled BIM BH3 peptide
Hadji, A., Schmitt, G. K., Schnorenberg, M. R., Roach, L. E., Hickey, C. M., Leak, L. B., Tirrell, M., & LaBelle, J. L. (2019) · Oncotarget · doi:10.18632/oncotarget.27262 · Cited by 16
Discovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancer
Lee, E. F., & Fairlie, W. D. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210749 · Cited by 18
MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment
Alcon, C., Martín, F., Prada, E., Mora, J., Soriano, A., Guillén, G., Gallego, S., Roma, J. M., Samitier, J., Villanueva, A., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00959-w · Cited by 18
Fu, Y., Jia, X., Yuan, J., Yang, Y., Zhang, T., Yu, Q., Zhou, J., & Wang, T. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.02.006 · Cited by 15
Gold, N. M., Ding, Q., Yang, Y., Pu, S.-Y., Cao, W., Ge, X., Yang, P., Okeke, M. N., Nisar, A., Pan, Y., et al. (2025) · MedComm · doi:10.1002/mco2.70086 · Cited by 15
Smith, M. L., Chyla, B., McKeegan, E. M., & Tahir, S. K. (2016) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21383 · Cited by 15
Self-citationManzari, M. T., Anderson, G. R., Lin, K., Soderquist, R. S., Çakır, M., Zhang, M. Y., Moore, C. E., Skelton, R. N., Fevre, M., Li, X., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw9162 · Cited by 15
Ren, Y., Huang, S.-H., Macedo, A. B., Ward, A. R., Alberto, W. D. C., Klevorn, T., Leyre, L., Copertino, D. C., Mota, T. M., Chan, D., et al. (2021) · Journal of Virology · doi:10.1128/jvi.02425-20 · Cited by 15
Kuzuoğlu‐Öztürk, D., Hu, Z., Rama, M., Devericks, E. N., Weiss, J., Chiang, G. G., Worland, S. T., Brenner, S. E., Goodarzi, H., Gilbert, L. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109321 · Cited by 16
Grubb, T. M., Maganti, S., Krill-Burger, J. M., Fraser, C. S., Stransky, L. A., Radivoyevitch, T., Sarosiek, K. A., Vázquez, F., Kaelin, W. G., & Chakraborty, A. A. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0669 · Cited by 18
MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53
Chang, M., Gao, F., Chen, J., Gnawali, G. R., & Wang, W. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-0022 · Cited by 18
Self-citationWeder, B., Mozaffari, M., Biedermann, L., Mamie, C., Moncsek, A., Wang, L., Clarke, S. H., Rogler, G., McRae, B. L., Graff, C. L., et al. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13151 · Cited by 12
Self-citationHussein, H. A. M., Okafor, I. B., Walker, L. R., Abdel-Raouf, U. M., & Akula, S. M. (2018) · Archives of Virology · doi:10.1007/s00705-018-3918-3 · Cited by 14
Bcl-xL inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas
Rello‐Varona, S., Fuentes-Guirado, M., López‐Alemany, R., Contreras-Pérez, A., Mulet-Margalef, N., García-Monclús, S., Tirado, Ò. M., & del Muro, X. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-40106-7 · Cited by 14
García, C. P., Videla-Richardson, G. A., Dimopoulos, N. A., Espinosa, D. D. F., Miriuka, S., Sevlever, G. E., Romorini, L., & Scassa, M. É. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152607 · Cited by 14
Tiedt, R., King, F. J., Stamm, C., Niederst, M. J., Delach, S. M., Zumstein-Mecker, S., Meltzer, J., Mulford, I. J., Labrot, E., Engstler, B. S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112297 · Cited by 13
Huang, R., Wang, H., Hong, J., Wang, Z., Wu, J., Huang, O., He, J., Chen, W., Li, Y., Chen, X., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1191910 · Cited by 14
Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma
Jacob, M., Wiedemann, S., Brücher, D., Pieper, N. M., Birkhold, M., Särchen, V., Jeroch, J., Demes, M. C., Gretser, S., Braun, Y., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02430-8 · Cited by 13
Gong, Q., Wang, H., Zhou, M., Zhou, L., Wang, R., & Li, Y. (2023) · Medicinal Research Reviews · doi:10.1002/med.21999 · Cited by 13
Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia
Rodríguez‐Medina, C., Stuckey, R., Bilbao, C., & Gómez‐Casares, M. T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031421 · Cited by 14
Biphenyl-dihydrothiazole-cyclized peptide libraries for peptide ligand and drug discovery
Liu, J.-J., Sun, X., Zhuang, J., Liu, Z., Xu, C., Wu, D., & Wu, C. (2025) · Science China Chemistry · doi:10.1007/s11426-024-2291-x · Cited by 14
Wang, Y., Liu, M., Chen, S., & Wu, Q. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8303 · Cited by 13
Chemical parsing: Dissecting cell dependencies with a toolkit of selective BCL-2 family inhibitors
Leverson, J. D. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1050155 · Cited by 13
Self-citationSelective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations
Henz, K., Al-Zebeeby, A., Başoğlu, M., Fulda, S., Cohen, G. M., Varadarajan, S., & Vogler, M. (2018) · Biological Chemistry · doi:10.1515/hsz-2018-0233 · Cited by 13
Barillé‐Nion, S., Lohard, S., & Juin, P. P. (2020) · Biomolecules · doi:10.3390/biom10081109 · Cited by 16
Bcl‐xL as prognostic marker and potential therapeutic target in cholangiocarcinoma
Hoffmeister‐Wittmann, P., Möck, A., Nichetti, F., Korell, F., Heilig, C. E., Scherr, A., Günther, M., Albrecht, T., Kelmendi, E., Xu, K., et al. (2022) · Liver International · doi:10.1111/liv.15392 · Cited by 12
Pasqua, L. G. D., Abdallah, M. M., Feletti, F., Vairetti, M., & Ferrigno, A. (2024) · Pharmaceuticals · doi:10.3390/ph17040484 · Cited by 13
Targeting Apoptotic Pathways in Acute Myeloid Leukaemia
Sillar, J. R., & Enjeti, A. K. (2019) · Cancers · doi:10.3390/cancers11111660 · Cited by 11
Targeting the B-cell lymphoma 2 anti-apoptotic proteins for cervical cancer treatment
Rahman, S. F. A., Lian, B. S. X., & Mohana‐Kumaran, N. (2020) · Future Oncology · doi:10.2217/fon-2020-0389 · Cited by 13
Rahman, S. F. A., Azlan, A., Lo, K. W., Azzam, G., & Mohana‐Kumaran, N. (2022) · Discover Oncology · doi:10.1007/s12672-022-00470-9 · Cited by 12
Doan, L., Paine, P., Tran, C., Parsons, B., Hiller, A., Joshua, I., Collaco, N., Vitari, A., de Morrée, A., Ishak, H. D., et al. (2020) · doi:10.21203/rs.3.rs-92962/v1 · Cited by 14
FOXM1 induces therapy resistance and inhibits apoptosis in a variety of human cancers
Raghuwanshi, S., & Gartel, A. L. (2026) · Cell Death and Disease · doi:10.1038/s41419-025-08321-5 · Cited by 13
Energetic Fingerprinting of Ligand Binding to Paralogous Proteins: The Case of the Apoptotic Pathway
Ivanov, S. M., Huber, R. G., Alibay, I., Warwicker, J., & Bond, P. J. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00765 · Cited by 12
Pesch, A. M., Chandler, B. C., Michmerhuizen, A. R., Carter, H. M., Hirsh, N. H., Wilder-Romans, K., Liu, M., Ward, T., Ritter, C. L., Nino, C. A., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0024 · Cited by 12
Bcl-xL activity influences outcome of the mitotic arrest
Suleimenov, M., Bekbayev, S., Ten, M., Suleimenova, N., Tlegenova, M., Nurmagambetova, A., Kauanova, S., & Vorobjev, I. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.933112 · Cited by 11
Radisavljević, S., Kesić, A., Ćoćić, D., Marković, V., Milovanović, J., Petrović, B., & Simović, A. R. (2022) · Applied Organometallic Chemistry · doi:10.1002/aoc.6922 · Cited by 11
Gargiulo, E., Teglgaard, R. S., Faitová, T., & Niemann, C. U. (2023) · Acta Haematologica · doi:10.1159/000533234 · Cited by 13
Bcl-x short-isoform is essential for maintaining homeostasis of multiple tissues
Keller, M. A., Huang, C.-Y., Ivessa, A., Singh, S., Romanienko, P. J., & Nakamura, M. (2023) · iScience · doi:10.1016/j.isci.2023.106409 · Cited by 11
Yedida, G., Milani, M., Cohen, G. M., & Varadarajan, S. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1759-y · Cited by 11
Knoll, G., Riffelsberger, P., Raats, D., Kranenburg, O., & Ehrenschwender, M. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2446-8 · Cited by 13
BCL‐XL exerts a protective role against anemia caused by radiation‐induced kidney damage
Brinkmann, K., Waring, P., Glaser, S. P., Wimmer, V. C., Cottle, D. L., Tham, M. S., Nhu, D., Whitehead, L. W., Delbridge, A. R. D., Lessène, G., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2020105561 · Cited by 10
Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-XL and BCL-2
Roy, M. J., Vom, A., Okamoto, T., Smith, B. J., Birkinshaw, R. W., Yang, H. J., Abdo, H., White, C. A., Segal, D., Huang, D. C. S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01771 · Cited by 11
Qin, X., Presser, A. G., Johnson, L., Matoba, Y., Shay, B., Xu, W., Choiniere, J., Fraser, C., Garbicz, F., Spetz, J. K. E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.24.661170 · Cited by 11
Novais, E. J., Ottone, O. K., Jagannath, S., Akande, E. J., Barve, R. A., & Risbud, M. V. (2026) · Bone Research · doi:10.1038/s41413-026-00526-4 · Cited by 10
Huber, H., Edenhofer, S., Estenfelder, S., & Stilgenbauer, S. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s102646 · Cited by 10
Yamamoto, M., Suzuki, S., Togashi, K., Sugai, A., Okada, M., & Kitanaka, C. (2022) · Cancers · doi:10.3390/cancers14071706 · Cited by 10
Ludwig, L. M., Roach, L. E., Katz, S. G., & LaBelle, J. L. (2020) · APOPTOSIS · doi:10.1007/s10495-020-01593-6 · Cited by 11
Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia
Smith, V. M., Lomas, O., Constantine, D., Palmer, L., Schuh, A., Bruce, D., Gonchar, O., Macip, S., Jayne, S., Dyer, M. J. S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000917 · Cited by 10
Marca, J. E. L., Kelly, G. L., Strasser, A., & Diepstraten, S. T. (2024) · Developmental Cell · doi:10.1016/j.devcel.2024.06.018 · Cited by 9
Lian, S. X. B., Lo, K. W., Khoo, S.-B. A., & Mohana‐Kumaran, N. (2020) · Tropical Life Sciences Research · doi:10.21315/tlsr2020.31.3.1 · Cited by 9
Genome-wide CRISPR screen reveals the synthetic lethality between BCL2L1 inhibition and radiotherapy
Yin, L., Hu, X., Pei, G., Tang, M., Zhou, Y., Zhang, H., Huang, M., Li, S., Zhang, J., Citu, C., et al. (2024) · Life Science Alliance · doi:10.26508/lsa.202302353 · Cited by 8
Self-citationAlmudimeegh, S., Almutairi, M. M., Softah, A., Alhazzani, K., Binobaid, L., Alshammari, M. A., Sobeai, H. M. A., Saleh, T., Alotaibi, M. R., & Alhoshani, A. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00034-2 · Cited by 8
The carboxyl-terminal sequence of PUMA binds to both anti-apoptotic proteins and membranes
Pemberton, J. M., Nguyen, D. Q., Osterlund, E. J., Schormann, W., Pogmore, J. P., Hirmiz, N., Leber, B. F., & Andrews, D. W. (2023) · eLife · doi:10.7554/elife.88329 · Cited by 8
Muhammed Favas, K. T., Semwal, M., Yoosuf, B. T., Lad, D. P., & Bansal, D. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05676-1 · Cited by 10
Bilardi, R. A., Anstee, N. S., Glaser, S. P., Robati, M., Vandenberg, C. J., & Cory, S. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.258 · Cited by 8
Metadata
- Authors
- Leverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., Lowes, K. N., Kovar, P., Chen, J., Jin, S., Smith, M., Xue, J., Zhang, H., Oleksijew, A., Magoc, T. J., Vaidya, K. S., Albert, D. H., Tarrant, J. M., La, N., Wang, L., Tao, Z.-F., Wendt, M. D., Sampath, D., Rosenberg, S. H., Tse, C., S. Huang, D. C., Fairbrother, W. J., Elmore, S. W., & Souers, A. J.
- Affiliations
- AbbVie (United States) (US)
- Genentech (US)
- AbbVie Inc., North Chicago, IL 60064, USA.
- The University of Melbourne (AU)
- Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
- Corresponding author
- Leverson, Joel D.
- Ma, Xiaoju Max
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2015-03-18
- Volume
- 7
- Issue
- 279
- Pages
- 279ra40-279ra40
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2110525250
- Cited by
- 541
- References
- 51
- Citations by year
- 2026: 22 · 2025: 33 · 2024: 34 · 2023: 38 · 2022: 58 · 2021: 56 · 2020: 69 · 2019: 49 · 2018: 58 · 2017: 65 · 2016: 43 · 2015: 12
- FWCI
- 25.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- Medical Research Council (461219, 461221, 1016701)
- Australian Cancer Research Foundation
- Cancer Council Victoria
- Australian National Health
- Independent Research Institutes Infrastructure Support Scheme (361646)
- Victorian State Government Operational Infrastructure Support
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- BCL-2 inhibitor, venetoclax, navitoclax, BCL-XL inhibition, A-1331852, docetaxel combination, neutropenia, thrombocytopenia, granulopoiesis, solid tumors, chronic lymphocytic leukemia
- MeSH terms
- Docetaxel, Administration, Oral, Aniline Compounds, Animals, Antineoplastic Agents, Cell Survival, Granulocytes, Humans, Isoquinolines, Kinetics, Neoplasm Transplantation, Neoplasms, Neutropenia, Neutrophils, Sulfonamides, Thrombocytopenia, Gene Expression Regulation, Neoplastic, Bridged Bicyclo Compounds, Heterocyclic, Proto-Oncogene Proteins c-bcl-2, Gene Expression Profiling, Taxoids, Cell Line, Tumor, bcl-X Protein, Mice, Benzothiazoles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
